Macrogenics Inc Stock Price, News & Analysis

MacroGenics (NASDAQ: MGNX) reported third-quarter 2025 results and corporate updates on Nov 12, 2025. The company had $146.4M in cash and marketable securities as of Sept 30, 2025, and expects to receive $75M in partnering payments from Sanofi and Gilead by year-end, extending cash runway into late 2027. Total revenue was $72.8M for Q3 2025 vs. $110.7M in Q3 2024. MacroGenics will stop developing lorigerlimab in second-line mCRPC after interim LORIKEET data but will continue the LINNET Phase 2 study in ovarian/gynecologic cancers. ADC programs MGC026, MGC028 and preclinical MGC030 remain active; an IND for MGC030 is planned for 2026.

MacroGenics (Nasdaq: MGNX) announced that President and CEO Eric Risser will participate in a fireside chat at the Stifel 2025 Healthcare Conference on Thursday, November 13, 2025 at 4:00 PM ET in New York.

A live webcast will be available via the company's Investor Relations "Events & Presentations" page and an archived replay will be maintained on the website for 30 days.

MacroGenics (NASDAQ:MGNX), a biopharmaceutical company specializing in antibody-based cancer therapeutics, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. President & CEO Eric Risser will deliver a presentation on Monday, September 8, 2025, at 11:30am ET in New York.

Investors can access the presentation webcast through the company's investor relations website, with a replay available for 30 days following the event.

MacroGenics (NASDAQ: MGNX) reported Q2 2025 financial results and outlined strategic priorities under newly-appointed CEO Eric Risser. The company received a $70 million upfront payment from Sagard Healthcare Partners for ZYNYZ® royalties and reported $176.5 million in cash and equivalents, extending runway through H1 2027.

Q2 2025 highlights include total revenue of $22.2 million (up from $10.8M in Q2 2024) and reduced net loss of $36.3 million (vs $55.7M in Q2 2024). The company is advancing multiple clinical programs, including lorigerlimab's Phase 2 trials and novel ADC pipeline development with MGC026, MGC028, and MGC030.

Strategic priorities include determining lorigerlimab's development path, advancing ADC programs, submitting MGC030 IND, and improving financial position through partnerships and asset monetization.

MacroGenics (NASDAQ: MGNX) has appointed Eric Risser as its new President, Chief Executive Officer, and Board member, effective August 13, 2025. Risser, who has served as Chief Operating Officer since 2022, succeeds Scott Koenig, M.D., Ph.D., who is stepping down after 24 years as CEO.

Risser brings nearly 30 years of biotech and pharmaceutical industry experience and has been with MacroGenics since 2009. Under his leadership in corporate development, the company has generated over $1.6 billion in non-dilutive capital. The outgoing CEO, Dr. Koenig, will continue to serve as Director and advisor, leaving a legacy of three FDA-approved products.

MacroGenics has entered into a royalty purchase agreement with Sagard Healthcare Partners for ZYNYZ (retifanlimab-dlwr), receiving a $70 million upfront payment. Under the agreement, Sagard will receive royalties on global net sales of ZYNYZ until reaching $140 million (2.0x return), after which MacroGenics will resume collecting all future royalties. MacroGenics maintains its other economic interests in ZYNYZ, including potential milestone payments and commercial manufacturing support. The company's cash position stands at $154.1 million as of March 31, 2025, and with this new payment and other anticipated revenues, MacroGenics expects to extend its cash runway through the first half of 2027.

MacroGenics (MGNX), a biopharmaceutical company specializing in antibody-based cancer therapeutics, has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference 2025. The company's management team will deliver a presentation on Tuesday, June 10, 2025, at 8:00am ET in Miami, FL. Interested parties can access the presentation webcast through the Investor Relations section of MacroGenics' website, specifically under the "Events & Presentations" tab. The webcast recording will remain available on the company's website for 30 days after the event.

MacroGenics (NASDAQ: MGNX) reported Q1 2025 financial results and corporate updates. The company's cash position stood at $154.1 million as of March 31, 2025. Key highlights include: First patient dosed in LINNET Phase 2 study of lorigerlimab for ovarian cancer, with clinical updates expected for LORIKEET Phase 2 study in H2 2025. Revenue increased to $13.2 million from $9.1 million YoY. Net loss improved to $41.0 million compared to $52.2 million in Q1 2024. The company is advancing its ADC pipeline with MGC026, MGC028, and MGC030. Notable partnered programs include MGD024 with Gilead, ZYNYZ with Incyte, and TZIELD with Sanofi. MacroGenics projects its cash runway into H2 2026.

MacroGenics (NASDAQ: MGNX), a biopharmaceutical company specializing in monoclonal antibody-based cancer therapeutics, has announced it will release its Q1 2025 financial results after market close on Tuesday, May 13, 2025. The company has stated it will not host a conference call to discuss the quarterly results or corporate progress for the period ending March 31, 2025, though it may resume quarterly conference calls in the future.